BioTuesdays Features Model Medicines’ AI-Driven Approach to Drug Discovery
Press Coverage
Patrick ONeill
BioTuesdays highlights how Model Medicines is combining AI, machine learning, medicinal chemistry, and biology to accelerate the discovery of novel therapeutics for diseases with high unmet medical need.
Patrick ONeill
Head of Partnerships and Investor Relations
BioTuesdays profiled Model Medicines’ work at the intersection of data science, biology, and drug development, highlighting the company’s proprietary GALILEO™ AI platform and its growing pipeline of AI-discovered therapeutics. The feature explores how Model Medicines is using its platform-driven approach to identify novel compounds across oncology, infectious disease, metabolic disorders, GI, neurology, autoimmune, and rare disease programs. The article also spotlights the company’s pan-antiviral candidate MDL-001 and oncology candidate MDL-4101 as examples of its AI-enabled discovery model.
Read the full article on BioTuesdays:
Model Medicines innovates by bringing together data science and biology to develop drugs
